**Table 1. Comparative characteristics of the patients**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter** | **Patients with SVD (Fazecas scale > 0) n = 54** | **Patients without SVD (Fazecas scale = 0) n = 63** | **P value** |
| Age, years (М ± SD) | 65 ± 9 | 51 ± 10 | < 0.001 |
| Male gender, n (%) | 51 (94.4) | 60 (95.2) | 1.0 |
| Female gender, n (%) | 3 (5.6) | 3 (4.8) | 1.0 |
| Arterial hypertension, n (%) | 51 (94.4) | 36 (57.1) | < 0.001 |
| Diabetes mellitus, n (%) | 11 (20.4) | 4 (6.3) | 0.029 |
| Hypercholesterolemia, n (%) | 42 (77.8) | 40 (64.5) | 0.153 |
| Atrial fibrillation, n (%) | 11 (20.4) | 5 (8.1) | 0.064 |
| Smokers, n (%) | 15 (27.8) | 18 (29.0) | 1.0 |
| Thrombotic events, n (%) | 25 (46.3) | 6 (9.5) | < 0.001 |

SVD, small vessel disease

**Table 2. Comparative characteristics of laboratory parameters of the fibrinolytic system, endothelial dysfunction and inflammation in the patients with magnetic resonance imaging markers of white matter lesions by the Fazecas scale and without such lesions, М ± SD / Me [Q25–Q75]**

|  |  |  |  |
| --- | --- | --- | --- |
| **Parameter (reference range)** | **Patients with SVD (Fazecas scale > 0) n = 54** | **Patients without SVD (Fazecas scale = 0) n = 63** | **P value** |
| Fibrinolytic abnormalities |
| XIIа-dependent fibrinolysis, min (5–12) | 7.6 ± 2.9 | 6.5 ± 1.7 | 0.032 |
| Plasminogen, % (75–140) | 91 [83–100] | 94 [86–106] | 0.325 |
| Alpha2-antiplasmin, % (80–120) | 111 [95–117] | 105 [95–111] | 0.016 |
| PAI-1, E/mL (7.0–43.0) | 13.4 [9.3–42.5] | 12.9 [8.3–40.1] | 0.898 |
| Thrombodynamics assay |
| V, mcm/min (20–29) | 36.2 [30.7–46.2] | 30.8 [27.3–38.9] | 0.004 |
| D, U (15000–32000) | 22789 [20567–26411] | 20627 [18324–22650] | < 0.001 |
| Endothelial dysfunction and inflammation parameters |
| FW, % (60–150) | 173 ± 56 | 145 ± 45 | 0.051 |
| hsCRP, mg/L (0.0–14.0) | 2.67 [0.90–6.60] | 0.87 [0.44–2.04] | 0.005 |
| Fibrinogen, g/L (1.6–4.6) | 3.17 ± 0.82 | 2.85 ± 0.53 | 0.099 |
| FVIII, % (50–150) | 165 ± 52 | 151 ± 48 | 0.167 |

D, clot density; hsCRP, highly sensitive C-reactive protein; PAI-1, plasminogen activator inhibitor type 1; SVD, small vessel disease; V, clot growth velocity

**Table 3. The probability model statistics for grade ≥ 2 periventricular and subcortical leukoareosis by the Fazecas scale**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Predictor** | **B** | **SE** | **P value** | **OR** | **95% CI** |
| XIIа-dependent fibrinolysis, min | 0.27 | 0.1 | 0.009 | 1.31 | 1.07–1.60 |
| Plasminogen, % | -0.033 | 0.009 | < 0.001 | 0.97 | 0.95–0.98 |

В, regression coefficient; CI, confidence interval; OR, odds ratio; SE, standard error

**Table 4. Statistics for the linear regression models variables**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **R2** | **B** | **SE** | **t** | **P value** |
| Model 1 |
| Intercept | – | 6.695 | 0.308 | 21.7 | < 0.001 |
| Number of gliosis areas | 0.093 | 0.073 | 0.026 | 2.9 | 0.006 |
| Model 2 |
| Intercept | – | 6.607 | 0.336 | 19.7 | < 0.001 |
| Size of gliosis areas | 0.079 | 0.164 | 0.063 | 2.6 | 0.010 |

В, regression coefficient; R2, determination coefficient; SE, standard error; t, Student's t test